Skip to main content

Table 2 Overall response rate to the treatment and polymorphisms observed

From: Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

Global distribution of polymorphisms (Pol)

Response N (%)

Stabilization or progression N (%)

p value

VNTR

2R/2R

7 (77.8)

2 (22.2)

0.055

3R/3R

7 (100)

0 (0)

2R/3R

4 (50)

4 (50)

3R/4R

0 (0)

1 (100)

Pol VNTR (Subanalysis by EGFR status; group of native EGFR-patients)

2R/2R

7 (77.8)

2 (22.2)

0.017

3R/3R

7 (100)

0 (0)

2R/3R

2 (33.3)

4 (66.7)

3R/4R

0 (0)

1 (100)

Global distribution of SNP

Absence

6 (85.7)

1 (14.3)

0.626

Presence

12 (66.7)

6 (33.3)

Global distribution of polymorphisms in 3′-UTR

+6/+6

10 (83.3)

2 (16.7)

0.234

+6/-6

6 (54.5)

5 (45.5)

-6/-6

2 (100)

0 (0)

Pol 3′-UTR (Subanalysis by smoking habit stratification; group of active and former smokers)

+6/+6

8 (100)

0 (0)

0.085

+6/-6

4 (50)

4 (50)

-6/-6

2 (100)

0 (0)